We are a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. Our pipeline is comprised of cell-based therapies for cancer and immune disorders. Our cellular immunotherapies are based on our novel ex vivo cell programming approach, which we apply to modulate the therapeutic function and direct the fate of hematopoietic cells.
Press Releases
Mar
16
2017
Fate Therapeutics Reports Fourth Quarter 2016 Financial Results
Read All »Events & Presentations
Mar
16
2017
